Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest HER2/neu Stories

2014-04-23 12:29:08

WORCESTER, Mass. and TORONTO, April 23, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that two abstracts in respect of results of the on-going Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer will be presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 30 to June 3, 2014. The ASCO Annual Meeting is the...

2014-04-10 12:26:46

Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and...

2014-04-09 16:24:00

NEW YORK, April 9, 2014 /PRNewswire/ -- The CementBloc, a leading healthwellness communications company headquartered in New York City, has been named a finalist in three out of ten categories at the upcoming 2014 DTC National Advertising Awards, a premier industry event that annually recognizes creativity and marketing effectiveness in healthcare. The CementBloc is a finalist for Best Launch, Best Website, and Best Digital Media, all for the Afinitor MORE campaign created for...

2014-04-08 13:04:46

Trial identifies breast cancer patients likely to benefit from experimental drug In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. Additionally, researchers learned that an algorithm used in the adaptive, randomized trial known as I-SPY 2 was highly effective at predicting the success of the treatment regimen in the...

2014-04-04 23:36:36

Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society continues research for breast cancer, several options have emerged. Of these options three drugs have been approved by the FDA for usage as treatment and no one is more excited than Dr. Mai Brooks. Perjeta (pertuzumab) In September 2013, the FDA approved Perjeta for use in combination with Herceptin (trastuzumab) and docetaxel for the...

Gregory Tsongalis PhD
2014-03-26 03:00:14

Norris Cotton Cancer Center, Dartmouth College Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer. The paper entitled "Personalized Therapy for Breast Cancer" was accepted on March 17, 2014, for publication in Clinical Genetics. The paper discusses targeted therapies, new biomarkers, and the quality of commercially available testing methods....

2014-03-25 12:29:41

Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014 /PRNewswire/ -- Decision Resources Group finds that efficacy more than any other factors drives oncologists' prescribing of targeted therapies for breast cancer and, according to the majority of surveyed oncologists, the escalating overall cost of drug treatment for breast cancer has little or no impact...

2014-03-24 20:22:55

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/czqbv2/investigation) has announced the addition of the "Investigation Report on China Trastuzumab Market, 2009-2018" [http://www.researchandmarkets.com/research/czqbv2/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main...

2014-03-19 20:21:22

-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global...

2014-03-18 12:31:29

The Majority of Surveyed Oncologists Have Already Prescribed Kadcyla, Just Nine Months Post-Launch, According to Findings from Decision Resources Group BURLINGTON, Mass., March 18, 2014 /PRNewswire/ -- Decision Resources Group finds that, at 18-months post-launch, over 85 percent of surveyed oncologists have prescribed Roche/Genentech's Perjeta for metastatic HER2-positive breast cancer. Since the last wave of the report was fielded six months previously, the average number of Perjeta-treated...